All productsPT-141
Size
- 10 mg — $40.00 CAD — Available
Research focus
Bremelanotide has been studied in controlled trials of hypoactive sexual desire disorder.
In simple words
PT-141, also called bremelanotide, is a peptide studied in signalling associated with sexual desire. The selected human trials concern a defined clinical population and study formulation, not this catalogue vial.
PT-141 is commonly called bremelanotide. Trial formulations and populations must not be equated with this listing.
Research references
Reviewed 2026-10-26
Human — randomized phase 3 trials
1,267 premenopausal women randomized; 1,202 in the efficacy analysis.
Trials in hypoactive sexual desire disorder reported improvements in desire and related distress scores compared with placebo.
Nausea, flushing and headache were more frequent. This selected population and tested formulation do not establish general sexual-performance benefits or validate this vial.
PMID 31599840. Open full text checked through Europe PMC on 2026-10-26. Selected evidence, not a systematic review.
Resources
Compound name and formula checked via PubChem PUG REST. This reference does not verify the vial, salt or formulation.
PubChemMechanism and target search. Automated access returned 403; DrugBank was not used to substantiate claims or approval status.
DrugBankProtein/precursor search, not a record of the supplied vial. Synthetic compounds and lab supplies may have no matching protein entry.
UniProtBioactivity search. Assay results depend on the tested compound, target and experimental conditions.
ChEMBLExplore indexed literature. Search results are not supporting citations; selected verified publications appear above.
PubMedExplore registrations. A match or completed study does not establish efficacy, approval or relevance to this vial.
ClinicalTrials.govEvidence on studied compounds does not establish the identity, purity, safety, or regulatory approval of the catalogue vial. No Canadian regulatory status is assessed here.
Research questions about PT-141
What is PT-141?
PT-141, also called bremelanotide, is a peptide studied in signalling associated with sexual desire. The selected human trials concern a defined clinical population and study formulation, not this catalogue vial.
What types of research are cited for PT-141?
The PT-141 profile contains the following selected evidence. This is not a systematic review or a complete inventory of research.
Bremelanotide: two RECONNECT trials (2019): Human — randomized phase 3 trials
Publication: Bremelanotide: two RECONNECT trialsWho or what was studied in the selected PT-141 references?
Bremelanotide: two RECONNECT trials (2019): 1,267 premenopausal women randomized; 1,202 in the efficacy analysis.
Publication: Bremelanotide: two RECONNECT trialsWhat identity distinctions matter for PT-141?
PT-141 is commonly called bremelanotide. Trial formulations and populations must not be equated with this listing.
What do the selected PT-141 studies not establish?
Bremelanotide: two RECONNECT trials (2019): Nausea, flushing and headache were more frequent. This selected population and tested formulation do not establish general sexual-performance benefits or validate this vial.
Publication: Bremelanotide: two RECONNECT trialsThese studies do not establish the identity, purity, safety or effects of the MXC PT-141 vial. Findings in one formulation, population or experimental model should not be assumed to apply to another.